NCT05741073 Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC
| NCT ID | NCT05741073 |
| Status | Recruiting |
| Phase | — |
| Sponsor | EuMelaReg gGmbH |
| Condition | Basal Cell Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,300 participants |
| Start Date | 2023-06-30 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,300 participants in total. It began in 2023-06-30 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This current registry study will analyze real-world data to address questions about disease characteristics and treatment patterns in NMSC patients based on the European NMSC-Registry. The overall objective is to describe characteristics, management and treatment outcomes for patients presenting with advanced NMSC (cSCC/BCC) or HR-cSCC in routine clinical practice, independent of treatments used across different European regions.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged ≥18 years at index date 2. Patients documented in the European NMSC-registry fulfilling EMR quality standard 3. Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting OR Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2) OR Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3) Exclusion Criteria: 1\. Patients receiving treatment within a clinical trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05741073 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Basal Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05741073 currently recruiting?
Yes, NCT05741073 is actively recruiting participants. Contact the research team at alexandra.hansen@eumelareg.org for enrollment information.
Where is the NCT05741073 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT05741073 clinical trial?
NCT05741073 is sponsored by EuMelaReg gGmbH. The trial plans to enroll 1,300 participants.